Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.

Katsuyoshi MatsuokaMakoto NaganumaToshifumi HibiHirohito TsubouchiKiyoshi OketaniToshinori KatsurabaraSeiichiro HojoOsamu TakenakaTetsu KawanoToshio ImaiTakanori Kanai

Published in: Journal of gastroenterology and hepatology (2021)

E6011 was well-tolerated and might be effective in CD patients. These findings need to be clarified in a randomized controlled study.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
randomized controlled trial
clinical trial
patient reported